DRUG-RESISTANT TUBERCULOSIS: RECENT APPROACH IN POLYMER BASED NANOMEDICINE

作者: Jessy Shaji , Mahmood Shaikh

DOI: 10.22159/IJPPS.2016V8I10.11295

关键词:

摘要: Tuberculosis (TB) had been a leading chronic bacterial infection since decades. Current therapeutic management of Mycobacterium tuberculosis (MTB) is inadequate due to the lengthy course treatment, drug-related side effects and ill-planned therapy, these factors can lead failure emergence drug-resistant TB. The Multi-drug-resistant (MDR) TB needs treatment with second-line antitubercular drugs (ATDs) having higher cost. misuse ATDs may result in extremely (XDR) strain which very difficult treat require high doses resulting more toxicity effects. This review highlights need for novel drug delivery drug-susceptible resistant characteristics nanoparticulate system its approach MDR XDR are discussed. lung site pulmonary targeted helps achieving increased efficacy less dose further reducing toxicity. symbiotic association nanotechnology give rise an efficient inhalable polymer based containing better Various loaded nanocarrier systems like Alginate, PLGA, Chitosan Gelatin nanocarriers discussed detail. Thus, this current research nanomedicine their importance control

参考文章(62)
J. H. Grosset, T. G. Singer, W. R. Bishai, New drugs for the treatment of tuberculosis: hope and reality. International Journal of Tuberculosis and Lung Disease. ,vol. 16, pp. 1005- 1014 ,(2012) , 10.5588/IJTLD.12.0277
Sandra Suarez, Patrick O'Hara, Masha Kazantseva, Christian E. Newcomer, Roy Hopfer, David N. McMurray, Anthony J. Hickey, Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharmaceutical Research. ,vol. 18, pp. 1315- 1319 ,(2001) , 10.1023/A:1013094112861
Ying Zhang, William R Jacobs Jr, Catherine Vilchèze, Mechanisms of drug resistance in Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease. ,vol. 13, pp. 1320- 1330 ,(2009) , 10.1128/9781555817657.CH8
Laxman S. Meena, Rajni, Survival mechanisms of pathogenic Mycobacterium tuberculosis H37Rv FEBS Journal. ,vol. 277, pp. 2416- 2427 ,(2010) , 10.1111/J.1742-4658.2010.07666.X
Susmita Sarkar, Mavanur R Suresh, An Overview Of Tuberculosis Chemotherapy – A Literature Review Journal of Pharmacy and Pharmaceutical Sciences. ,vol. 14, pp. 148- 161 ,(2011) , 10.18433/J33591
Ranjita Shegokar, Loaye Al Shaal, Khalil Mitri, Present status of nanoparticle research for treatment of Tuberculosis Journal of Pharmacy and Pharmaceutical Sciences. ,vol. 14, pp. 100- 116 ,(2011) , 10.18433/J3M59P
Yashwant Gupta, Piush Khare, Aviral Jain, Anekant Jain, Sanjay K. Jain, Lathaeswari Ramalingam, Divya Bhargava, Lactose-Conjugated PLGA Nanoparticles for Enhanced Delivery of Rifampicin to the Lung for Effective Treatment of Pulmonary Tuberculosis. Pda Journal of Pharmaceutical Science and Technology. ,vol. 64, pp. 278- 287 ,(2010)
BM Yashodhara, Choo Beng Huat, Lakshmi Nagappa Naik, Shashikiran Umakanth, Manjunatha Hande, Joseph M Pappachan, None, Multidrug and extensively drug-resistant tuberculosis from a general practice perspective. Infection and Drug Resistance. ,vol. 3, pp. 115- 122 ,(2010) , 10.2147/IDR.S10743
Jean C. Sung, Danielle J. Padilla, Lucila Garcia-Contreras, Jarod L. VerBerkmoes, David Durbin, Charles A. Peloquin, Katharina J. Elbert, Anthony J. Hickey, David A. Edwards, Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery Pharmaceutical Research. ,vol. 26, pp. 1847- 1855 ,(2009) , 10.1007/S11095-009-9894-2